Recent Updates
Recently added Catalysts
ZVRA Positive Sentiment

Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference

Key Takeaway: Zevra Therapeutics announced its participation in the Piper Sandler Annual Healthcare Conference on December 2, 2026. The executive leadership team will present, and one-on-one meetings will be available for attendees. The company focuses on bringing therapies to patients with rare diseases, particularly Niemann-Pick disease type C.

Market Sentiment Analysis

POSITIVE FACTORS

  • Zevra will present at a major healthcare conference.
  • Management will hold one-on-one meetings with attendees.
  • The company has a strong foundation with its lead product.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
9.5%
average across 4 past catalysts
Lead asset
ACER-002
Phase 3 · Vascular Ehlers-Danlos Syndrome

Full Press Release Details

BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company committed to redefining what's possible in bringing life-changing therapeutics to people living with rare diseases, today announced that members of Zevra’s executive leadership team will present at the Piper Sandler 38th Annual Healthcare Conference in New York, NY on Wednesday, December 2, 2026, at 1:00 p.m. ET.
Additionally, management will be available for one-on-one meetings with registered conference attendees. A link to the live webcast will be accessible on the “Events & Presentations” page in the Investor Relations section of Zevra’s website at investors.zevra.com.

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.
For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 9, 2026 and Zevra’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed on November 3, 2026, and Zevra's other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Frequently Asked Questions

When will Zevra present at the conference?

Zevra will present on December 2, 2026, at 1:00 p.m. ET.

Where will the conference take place?

The conference will be held in New York, NY.

What is Zevra's focus in therapeutics?

Zevra focuses on therapies for rare diseases, including Niemann-Pick disease.

Will there be one-on-one meetings available?

Yes, management will be available for one-on-one meetings with attendees.

Last updated: Nov 18, 2026